Search research articles
Contact Us
Filters
Showing results (321-330 of 404) with videos related to
Page
of 41
Sort By:
Urologic Oncology
|
June 3, 2017
Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer
Roberto Iacovelli, Maria Cossu Rocca, Luca Galli, et al.
International Journal of Molecular Sciences
|
January 21, 2023
Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a)
Marco Stellato, Sebastiano Buti, Marco Maruzzo, et al.
The Oncologist
|
June 2, 2021
Prognostic Role of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma: A Large, Multicenter, Prospective Trial
Umberto Basso, Antonella Facchinetti, Elisabetta Rossi, et al.
Annals of Surgical Oncology
|
December 5, 2014
Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors
Matteo Santoni, Alessandro Conti, Stefano Partelli, et al.
Targeted Oncology
|
July 17, 2020
Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis
Roberto Iacovelli, Chiara Ciccarese, Gaetano Facchini, et al.
The Oncologist
|
November 17, 2025
Best therapeutic approach in metastatic hormone-sensitive prostate cancer based on disease volume: a systematic review and network meta-analysis
Fabrizio Di Costanzo, Chiara Mercinelli, Alessio Signori, et al.
Targeted Oncology
|
August 10, 2022
Concomitant Use of Statins, Metformin, or Proton Pump Inhibitors in Patients with Advanced Renal Cell Carcinoma Treated with First-Line Combination Therapies
Matteo Santoni, Javier Molina-Cerrillo, Zin W Myint, et al.
Plos One
|
April 18, 2015
The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: a new pharmacodynamic marker?
Francesco Pantano, Matteo Santoni, Giuseppe Procopio, et al.
Clinical & Experimental Metastasis
|
June 8, 2024
Pembrolizumab in patients with advanced upper tract urothelial carcinoma: a real-world study from ARON-2 project
Alessandro Rizzo, Sebastiano Buti, Patrizia Giannatempo, et al.
Targeted Oncology
|
August 29, 2020
Correction to: Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis
Roberto Iacovelli, Chiara Ciccarese, Gaetano Facchini, et al.
Page
of 41
Search research articles
Search
Showing results (321-330 of 404) with videos related to
Sort By:
Page
of 41
Urologic Oncology
|
June 3, 2017
Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer
Roberto Iacovelli, Maria Cossu Rocca, Luca Galli, et al.
International Journal of Molecular Sciences
|
January 21, 2023
Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a)
Marco Stellato, Sebastiano Buti, Marco Maruzzo, et al.
The Oncologist
|
June 2, 2021
Prognostic Role of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma: A Large, Multicenter, Prospective Trial
Umberto Basso, Antonella Facchinetti, Elisabetta Rossi, et al.
Annals of Surgical Oncology
|
December 5, 2014
Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors
Matteo Santoni, Alessandro Conti, Stefano Partelli, et al.
Targeted Oncology
|
July 17, 2020
Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis
Roberto Iacovelli, Chiara Ciccarese, Gaetano Facchini, et al.
The Oncologist
|
November 17, 2025
Best therapeutic approach in metastatic hormone-sensitive prostate cancer based on disease volume: a systematic review and network meta-analysis
Fabrizio Di Costanzo, Chiara Mercinelli, Alessio Signori, et al.
Targeted Oncology
|
August 10, 2022
Concomitant Use of Statins, Metformin, or Proton Pump Inhibitors in Patients with Advanced Renal Cell Carcinoma Treated with First-Line Combination Therapies
Matteo Santoni, Javier Molina-Cerrillo, Zin W Myint, et al.
Plos One
|
April 18, 2015
The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: a new pharmacodynamic marker?
Francesco Pantano, Matteo Santoni, Giuseppe Procopio, et al.
Clinical & Experimental Metastasis
|
June 8, 2024
Pembrolizumab in patients with advanced upper tract urothelial carcinoma: a real-world study from ARON-2 project
Alessandro Rizzo, Sebastiano Buti, Patrizia Giannatempo, et al.
Targeted Oncology
|
August 29, 2020
Correction to: Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis
Roberto Iacovelli, Chiara Ciccarese, Gaetano Facchini, et al.
Page
of 41